SCHEMBL4214294

SCHEMBL4214294

C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@H]3[C@@H](O)C[C@]2(C)[C@@]1(OC(=O)c1ccco1)C(=S)OF

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NR3C1 P04150 16/20 0.53
▸ PGR P06401 3/20 0.53
▸ LMNA P02545 2/20 0.53
▸ HIF1A Q16665 1/20 0.53
▸ NR1I2 O75469 1/20 0.53
▸ CNR1 P21554 1/20 0.53
▸ CYP3A4 P08684 2/20 0.52
▸ CYP1A2 P05177 1/20 0.52
▸ CYP2D6 P10635 1/20 0.52
▸ CYP2C9 P11712 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ ABCB11 O95342 1/20 0.52
▸ ADORA3 P0DMS8 1/20 0.52
▸ AR P10275 1/20 0.52
▸ PTGS1 P23219 1/20 0.52
▸ SLCO1B3 Q9NPD5 1/20 0.52
▸ SLCO1B1 Q9Y6L6 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14794113 0.90 NR3C1 (0.56) NR3C1PGRLMNAHIF1ANR1I2
SCHEMBL11036558 0.88 NR3C1 (0.64) NR3C1PGRLMNAHIF1ANR1I2
SCHEMBL11076081 0.88 NR3C1 (0.55) NR3C1PGRLMNAHIF1ANR1I2
SCHEMBL6906058 0.88 NR3C1 (0.68) NR3C1PGRLMNAHIF1ANR1I2
SCHEMBL13659043 0.88 NR3C1 (0.68) NR3C1PGRLMNAHIF1ANR1I2
SCHEMBL3982428 0.87 NR3C1 (0.60) NR3C1PGRLMNAHIF1ANR1I2
SCHEMBL14794076 0.85 NR3C1 (0.56) NR3C1PGRLMNAHIF1ANR1I2
SCHEMBL10030109 0.80 NR3C1 (0.51) NR3C1PGRLMNAHIF1ANR1I2
SCHEMBL12397376 0.80 NR3C1 (0.72) NR3C1PGR
SCHEMBL11307485 0.80 NR3C1 (0.61) NR3C1PGRLMNAHIF1ANR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8785425-B2 11β-hydroxyandrosta-4-ene-3-ones SUN PHARMA ADVANCED RESEARCH COMPANY LTD. 2014-07-22 — — US disclosed
US-20090054388-A1 NOVEL 11 BETA-HYDROXYANDROSTA-4-ENE-3-ONES SUN PHARMA ADVANCE RESEARCH COMPANY (IN) 2009-02-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054388-A1 NOVEL 11 BETA-HYDROXYANDROSTA-4-ENE-3-ONES HSD11B1, HSD3B1, HSD3B2 NR3C1 37/4885PGR 146/4885LMNA 1076/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback